摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

1,2-bis-isopentyloxy-ethane | 78617-93-3

中文名称
——
中文别名
——
英文名称
1,2-bis-isopentyloxy-ethane
英文别名
1,2-Bis-isopentyloxy-aethan;1,2-Bis(3-methylbutoxy)ethane;3-methyl-1-[2-(3-methylbutoxy)ethoxy]butane
1,2-bis-isopentyloxy-ethane化学式
CAS
78617-93-3
化学式
C12H26O2
mdl
——
分子量
202.337
InChiKey
BMJMPMPRZVKSLC-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    3.3
  • 重原子数:
    14
  • 可旋转键数:
    9
  • 环数:
    0.0
  • sp3杂化的碳原子比例:
    1.0
  • 拓扑面积:
    18.5
  • 氢给体数:
    0
  • 氢受体数:
    2

反应信息

点击查看最新优质反应信息

文献信息

  • NOVEL COMPOUNDS AND USES THEREOF
    申请人:ACCUTAR BIOTECHNOLOGY INC.
    公开号:US20180016269A1
    公开(公告)日:2018-01-18
    The present disclosure relates to novel compounds, pharmaceutical compositions containing such compounds, and their use in prevention and treatment of estrogen-related diseases and conditions.
    本公开涉及新化合物、含有此类化合物的药物组合物,以及它们在预防和治疗雌激素相关疾病和状况中的应用。
  • CEREBLON LIGANDS AND BIFUNCTIONAL COMPOUNDS COMPRISING THE SAME
    申请人:Arvinas, Inc.
    公开号:US20180215731A1
    公开(公告)日:2018-08-02
    The description relates to cereblon E3 ligase binding compounds, including bifunctional compounds comprising the same, which find utility as modulators of targeted ubiquitination, especially inhibitors of a variety of polypeptides and other proteins which are degraded and/or otherwise inhibited by bifunctional compounds according to the present disclosure. In particular, the description provides compounds, which contain on one end a ligand which binds to the cereblon E3 ubiquitin ligase and on the other end a moiety which binds a target protein such that the target protein is placed in proximity to the ubiquitin ligase to effect degradation (and inhibition) of that protein. Compounds can be synthesized that exhibit a broad range of pharmacological activities consistent with the degradation/inhibition of targeted polypeptides of nearly any type.
    该描述涉及cereblon E3连接酶结合化合物,包括包含相同成分的双功能化合物,这些化合物作为靶向泛素化的调节剂具有实用价值,尤其是抑制剂,可降解和/或以其他方式抑制根据本公开的双功能化合物。特别是,该描述提供了化合物,其一端含有与cereblon E3泛素连接酶结合的配体,另一端含有与目标蛋白结合的部分,使目标蛋白位于泛素连接酶附近以降解(和抑制)该蛋白。可以合成表现出广泛药理活性的化合物,与几乎所有类型的靶向多肽的降解/抑制一致。
  • CONJUGATES DERIVED FROM NON-STEROIDAL ANTI-INFLAMMATORY DRUGS AND METHODS OF USE THEREOF IN IMAGING
    申请人:Reiley Pharmaceuticals, Inc.
    公开号:US20150374858A1
    公开(公告)日:2015-12-31
    Conjugates derived from non-steroidal anti-inflammatory drugs (NSAIDs) and methods of use thereof are disclosed, useful for, inter alia, identifying and localizing the site of pathology and/or inflammation responsible for the sensation of pain in a patient; for identifying the sites of primary, secondary, benign, or malignant tumors; and for diagnosing infection or confirming or ruling out suspected infection. The NSAID-based conjugates contain an imaging moiety. The conjugates concentrate at sites of increased cyclooxygenase expression, thus revealing the sites of increased prostaglandin production, which is correlated with pain and inflammation, and correlated with tumor presence and/or location. Identifying areas of increased COX expressing can also aid in screening for infections.
    披露了来自非甾体抗炎药(NSAIDs)的衍生物及其使用方法,这对于识别和定位患者疼痛感觉的病理和/或炎症部位;识别原发、继发、良性或恶性肿瘤的部位;以及诊断感染或确认或排除疑似感染非常有用。基于NSAID的偶联物含有成像基团。这些偶联物在环氧化酶表达增加的部位富集,从而揭示了前列腺素产生增加的部位,这与疼痛和炎症有关,并与肿瘤存在和/或位置有关。识别COX表达增加的区域也有助于筛查感染。
  • MDM2-BASED MODULATORS OF PROTEOLYSIS AND ASSOCIATED METHODS OF USE
    申请人:Arvinas, Inc.
    公开号:US20170008904A1
    公开(公告)日:2017-01-12
    The description relates to MDM2 binding compounds, including bifunctional compounds comprising the same, which find utility as modulators of targeted ubiquitination, especially inhibitors of a variety of polypeptides and other proteins which are degraded and/or otherwise inhibited by bifunctional compounds according to the present invention. In particular, the description provides compounds, which contain on one end a ligand which binds to the MDM2 E3 ubiquitin ligase and on the other end a moiety which binds a target protein such that the target protein is placed in proximity to the ubiquitin ligase to effect degradation (and inhibition) of that protein. Compounds can be synthesized that exhibit a broad range of pharmacological activities consistent with the degradation/inhibition of targeted polypeptides of nearly any type.
    描述涉及MDM2结合化合物,包括包含相同结构的双功能化合物,这些化合物可作为靶向泛素化的调节剂,特别是根据本发明抑制各种多肽和其他蛋白质的化合物。具体而言,描述提供了一种化合物,其一端含有结合到MDM2 E3泛素连接酶的配体,另一端含有结合到靶蛋白的基团,使得靶蛋白与泛素连接酶靠近,以促使该蛋白的降解(和抑制)。可以合成出一系列具有广泛药理活性的化合物,与几乎任何类型的靶向多肽的降解/抑制一致。
  • COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF RAPIDLY ACCELERATED FIBROSARCOMA POLYPEPTIDES
    申请人:Arvinas, Inc.
    公开号:US20180179183A1
    公开(公告)日:2018-06-28
    The present disclosure relates to bifunctional compounds, which find utility as modulators of Rapidly Accelerated Fibrosarcoma (RAF, such as c-RAF, A-RAF and/or B-RAF; the target protein). In particular, the present disclosure is directed to bifunctional compounds, which contain on one end a Von Hippel-Lindau, cereblon, Inhibitors of Apotosis Proteins or mouse double-minute homolog 2 ligand which binds to the respective E3 ubiquitin ligase and on the other end a moiety which binds the target protein RAF, such that the target protein is placed in proximity to the ubiquitin ligase to effect degradation (and inhibition) of target protein. The present disclosure exhibits a broad range of pharmacological activities associated with degradation/inhibition of target protein. Diseases or disorders that result from aggregation or accumulation of the target protein, or the constitutive activation of the target protein, are treated or prevented with compounds and compositions of the present disclosure.
    本公开涉及双功能化合物,其作为快速加速纤维肉瘤(RAF,如c-RAF、A-RAF和/或B-RAF;目标蛋白)的调节剂而发挥作用。具体而言,本公开涉及含有一端为Von Hippel-Lindau、cereblon、凋亡抑制蛋白或鼠双分子同源物2配体的双功能化合物,该配体与相应的E3泛素连接酶结合,并且另一端含有结合目标蛋白RAF的基团,使得目标蛋白与泛素连接酶靠近,以实现目标蛋白的降解(和抑制)。本公开展示了与目标蛋白的降解/抑制相关的广泛药理活性范围。本公开的化合物和组合物用于治疗或预防由目标蛋白的聚集或积累,或目标蛋白的构成性激活导致的疾病或紊乱。
查看更多